Abstracts tagged "Autoantibody(ies)"

Abstract Number: 0344 • ACR Convergence 2024
Characteristics of Patients with Antisynthetase Antibodies
Danny Kasto¹, Michael McLucas², Anne-Marie Aubin², Armando Faigl² and Gabor Major¹, ¹Dep of Rheumatology Royal Newcastle Centre / John Hunter Hospital, Rankin Park, New South Wales, Australia, ²Dep of Rheumatology Royal Newcastle Centre / John Hunter Hospital, Rankin Park, Australia
Background/Purpose: Aminoacyl transfer RNA synthetase antibodies (ASAbs) are associated with a range of clinical manifestations, including severe lung and muscle disease and are postulated to…
Abstract Number: 0838 • ACR Convergence 2024
The Mechanistic Impact of IgA anti-beta-2 Glycoprotein I on Accelerated Atherosclerosis in Primary APS
Kavya Sugur¹, Emily Chong¹, Srilakshmi Yalavarthi², Katarina Kmetova³, Lyndsay Kluge¹, Wenying Liang², Cyrus Sarosh⁴, NaveenKumar Somanathapura K², Jacqueline Madison², Ajay Tambralli², Jason Knight² and Yu Zuo², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁴University of Michigan, Temperance, MI
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease characterized by persistent antiphospholipid antibodies (aPL). APS patients experience significant morbidity and mortality, much of which…
Abstract Number: 1427 • ACR Convergence 2024
Observed and Simulated Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Fully Human FcRn Blocking Monoclonal Antibody, in Adults with Sjögren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study
Sophia G. Liva¹, fudan Zheng¹, Jocelyn H. Leu², Kathy Sivils³, Keying Ma¹, He Li⁴, Steven Leonardo⁵, Kim Lo¹, Jada Idokogi¹, Kim Campbell¹ and Jonathan J. Hubbard¹, ¹Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA, ³Johnson & Johnson Innovative Medicine, Edmond, OK, ⁴Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, ⁵Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA
Background/Purpose: Sjögren’s disease (SjD) is a chronic, progressive autoimmune disease characterized by aberrant B lymphocyte activity, elevated IgG production, and the presence of IgG autoantibodies…
Abstract Number: 1652 • ACR Convergence 2024
Extracellular Vesicles from Lymphocyte B and Neutrophil Presents Ro52, Ro60 and La Autoantigens in Patient Suffering from Sjögren Syndrome
Lily BRUYERE¹, Anne-Claire DUCHEZ², Martin KILLIAN³ and Stéphane PAUL⁴, ¹université jean-monnet, saint-etienne, ²EFS, saint-etienne, ³chu Saint-Etienne, saint-etienne, ⁴CIRI, Saint Etienne, France
Background/Purpose: Extracellular Vesicles (EVs) are double lipid bilayer-enclosed membranous vesicles, produced and discharged from almost all cells. EVs are known for inter-cellular communication by releasing…
Abstract Number: 2059 • ACR Convergence 2024
The Rs35705950 Promoter Variant of Muc5b Is Associated with Usual Interstitial Pneumonia in Antisynthetase Syndrome
Daphne Rivero Gallegos¹, Mayra Mejía², Karol J. Nava-Quiroz², Heidegger N. Mateos-Toledo³, Héctor I. Rocha-González⁴, Juan C. Huerta-Cruz³, Espiridion Ramos-Martínez⁵, Gloria Pérez-Rubio³, Ingrid Fricke-Galindo³, Jorge Rojas-Serrano⁶ and Ramcés Falfán-Valencia³, ¹INER, Ciudad de México, Mexico State, Mexico, ²INER, Mexico, Distrito Federal, Mexico, ³INER, Mexico City, Distrito Federal, Mexico, ⁴Instituto Politècnico Nacional, Mexico City, Distrito Federal, Mexico, ⁵UNAM, Ciudad de Mexico, Distrito Federal, Mexico, ⁶National Institute of Respiratory Diseases, Ismael Cosío Villegas, Mexico City, Mexico
Background/Purpose: Rs35705950 variant in the MUC5B gene promoter is a critical genetic risk factor in idiopathic pulmonary fibrosis (IPF). It has been associated with usual…
Abstract Number: 2447 • ACR Convergence 2024
Features of Anti-Fibrillarin Positive Systemic Sclerosis Patients and Ethnic Differences: A European Multicenter Cohort
Roberto D'Alessandro¹, Stefano Rodolfi², Alix Calot¹, Louis Bébéar³, Corrado Campochiaro⁴, Veronica Codullo⁵, Francesco Del Galdo⁶, Ivan Castellvi Barranco⁷, Elisabetta Zanatta⁸, Silvia Bellando Randone⁹, Goncalo Boleto¹⁰, Loic Raffray¹¹, Emmanuel Chatelus¹², Patrice Cacoub¹³, Alexandre Le Joncour¹³, Paolo Airò¹⁴, cristiana sieiro santos¹⁵, Alain Lescoat¹⁶, Jérôme Avouac¹⁷, Christopher Denton¹⁸ and Yannick Allanore¹⁹, ¹Rheumatology Department, Cochin Hospital, Université Paris Cité, APHP, Paris, France, Paris, France, ²Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, UK, London, United Kingdom, ³Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, France., Bordeaux, France, ⁴IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ⁵Division of Rheumatology - Policlinico San Matteo, Pavia, Italy, Pavia, Lombardia, Italy, ⁶University of Leeds, Leeds, United Kingdom, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁸Unit of Rheumatology, Padova University, Padova, Italy, ⁹Department of Experimental and Clinical Medicine University of Florence Division of Rheumatology Scleroderma Unit, Careggi Hospital Florence, Italy, Florence, Toscana, Italy, ¹⁰Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal., Lisbon, Portugal, ¹¹CHU La Réunion - Competence center for autoimmune diseases, Internal Medicine, Saint-Denis, Reunion, ¹²Rheumatology department strasbourg, Strasbourg, France, ¹³Department of Internal Medicine and Clinical Immunology France, Centre national de référence maladies Autoimmunes Systémiques rares, Centre national de référence maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Pitié Salpetrière, 75013 Paris, France, Paris, France, ¹⁴Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ¹⁵Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ¹⁶Department of Internal Medicine and Clinical Immunology, Rennes University Hospital, Rennes, France, rennes, France, ¹⁷Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ¹⁸University College London, Northwood, United Kingdom, ¹⁹Rheumatology department, Université Paris Cité, Cochin Hospital of Paris; France, Paris, France
Background/Purpose: Anti-fibrillarin (AFA) auto-antibodies are rarely found in Systemic Sclerosis (SSc). Beyond the ethnic association with a higher prevalence in patients of Black ethnicity, the…
Abstract Number: 0064 • ACR Convergence 2024
Anti-Citrullinated Protein Antibodies Arise During Affinity Maturation of Germline-Encoded Antibodies to Carbamylated Proteins in Rheumatoid Arthritis
Marta Escarra-Senmarti¹, Michael Chungyoun², Dylan Ferris¹, Jeffrey Gray² and Felipe Andrade³, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²The Johns Hopkins Whiting School of Engineering, Baltimore, MD, ³The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: The production of antibodies to modified self-antigens is a hallmark in rheumatoid arthritis (RA). Antibodies to citrullinated (ACPAs) and carbamylated proteins (CarP) are of…
Abstract Number: 0346 • ACR Convergence 2024
Clonally Expanded and Total B Cells in Patients with Idiopathic Inflammatory Myopathies Show Skewed B Cell Subset Distribution and Reduced Somatic Hypermutation Relative to Healthy Controls
Amelia Sawyers¹, Leslie Crofford², Erin Wilfong³ and Rachel Bonami³, ¹Vanderbilt University School of Medicine, Nashville, TN, ²Vanderbilt University Medical Center, Melbourne, AR, ³Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a collection of rare, systemic rheumatic diseases. A role for B cells in IIM is indicated by the success…
Abstract Number: 0839 • ACR Convergence 2024
Comprehensive Single-cell Analysis Reveals Interferon Pathway Activation and Aberrant B Cell Dynamics in APS Autoimmunity
Haoyu Pan, Xiaohan Wei, Jinyi Qian, Shuyi Yu, Zhixia Yang, Zetao Ding, Chengde Yang and Hui Shi, Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic)
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized with the presence of pathogenic antiphospholipid antibodies (aPL) by autoreactive B cells. However, it remains…
Abstract Number: 1488 • ACR Convergence 2024
Clinical Utility and Performance of Anti-C1q Antibodies for Systemic Lupus Erythematosus: Comparative Analysis of Three Different Assays
Mariana Gonzalez-Trevino¹, MeLea Hetrick¹, Alain Sanchez-Rodriguez², Ali Duarte-Garcia¹ and Anne Tebo³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
Background/Purpose: SLE is an autoimmune disorder characterized by autoantibody-mediated tissue damage. Antibodies against C1q (anti-C1q) can identify patients with LN and rising titers predict renal…
Abstract Number: 1684 • ACR Convergence 2024
Autoantibodies to Transcription Factor a Mitochondria Are Associated with Damage Accrual, Malignancy Risk and Mortality in SLE
Eduardo Gomez¹, Daniel Goldman², Merlin Paz³, Michelle Petri² and Felipe Andrade⁴, ¹The Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³Johns Hopkins Medicine, Baltimore, MD, ⁴The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: We recently identified autoantibodies in SLE that target transcription factor A mitochondrial (TFAM), a critical protein in mitochondrial DNA transcription and packaging1. These autoantibodies…
Abstract Number: 2065 • ACR Convergence 2024
Proposed Pathways Involved in the Pathogenesis of Juvenile Dermatomyositis (JDM)
Samantha Coss¹, Danlei Zhou¹, Rabheh Abdul Aziz², Katherine Miller³, Shoghik Akoghlanian⁴, Kyla Driest¹, Edward Oberle¹, Vidya Sivaraman⁵, Charles Spencer⁶, Stacy Ardoin¹ and Chack-Yung Yu⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²University at Buffalo, Buffalo, NY, ³Nationwide Children's Hospital, Institute for Genomic Medicine, Columbus, OH, ⁴Nationwide Children�s Hospital, Columbus, OH, ⁵Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ⁶University of Mississippi Medical Center, Jackson, MS, ⁷Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, OH
Background/Purpose: JDM is an autoimmune disease of skin and muscle. We investigated genetic factors, autoantibodies, and clinical features in JDM.Methods: Subjects came from 2 large…
Abstract Number: 2471 • ACR Convergence 2024
Association of Telangiectasias with Autoantibodies and Clinical Manifestations in Systemic Sclerosis
Namitha Nair¹, Thomas Medsger, Jr², Robert Lafyatis³, Maureen Laffoon⁴, Leigh Freno⁴ and Robyn Domsic⁵, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴UPMC, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Telangiectasias (Tel) are visibly dilated cutaneous post-capillary venules reported to occur in about 75% of patients with systemic sclerosis (SSc), making them a common…
Abstract Number: 0098 • ACR Convergence 2024
Anti-HSP90α as a Protective Natural Antibody Against Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus
Marina Barguil Macedo¹, Jorge Armando Gonzalez-Chapa¹, Anders Bengtsson², Iva Gunnarsson³, Elisabet Svenungsson⁴ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Lund University, Lund, Sweden, ³Karolinska Institute, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Heat shock protein 90 alpha (HSP90α) is an epichaperone present ubiquitously inside the cell, whose dimers function as a foldase that helps the correct…
Abstract Number: 0444 • ACR Convergence 2024
Deep Serologic Profiling Identifies Novel Autoantibodies Associated with Fetal Atrioventricular Block
Philip Carlucci¹, Robert Clancy², Mala Masson³, Colin Phoon⁴, Ashley Roman⁴, Peter Izmirly⁵, Amit Saxena⁶, H Michael Belmont⁴, Christina Penfield⁴, Young Mi Lee⁴, Julie Nusbaum⁷, Andrew Rubenstein⁴, Ruben Acherman⁸, Elena Sinkovskaya⁹, Alfred Abuhamad⁹, Karla Bermudez-Wagner⁹, Majd Makhoul¹⁰, Gary Satou¹¹, Whitnee Hogan¹², Nelangi Pinto¹³, Anita Moon-Grady¹⁴, Lisa Howley¹⁵, Mary Donofrio¹⁶, Anita Krishnan¹⁶, Jaclyn Phillips¹⁷, Stephanie Levasseur¹⁸, Miwa Geiger¹⁹, Erin Paul²⁰, Sonal Owens²¹, Kristopher Cumbermack²², Jyothi Matta²³, Gary Joffe²⁴, Christopher Lindblade²⁵, Carl Weiner²⁶, Caitlin Haxel²⁷, Katherine Kohari²⁸, Joshua Copel²⁸, James Strainic²⁹, Tam Doan³⁰, Shreya Sheth³⁰, Stacy Killen³¹, Theresa Tacy³², Michelle Kaplinski³², Nicola Fraser⁴, Kelly Ruggles³³, Bettina Cuneo³⁴ and Jill Buyon³⁵, ¹New York University School of Medicine, New York, NY, ²Columbia University Medical Center, New York, NY, ³NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁴NYU Langone Health, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷NYU Langone Hospital - Long Island, Internal Medicine - Rheumatology, Mineola, NY, ⁸Children's Heart Center, Las Vegas, NV, ⁹Eastern Virginia Medical School, Norfolk, VA, ¹⁰Atrium Health Levine Children's Hospital, Charlotte, NC, ¹¹University of California Los Angeles, Los Angeles, CA, ¹²University of Utah, Salt Lake City, UT, ¹³Seattle Children's Hospital, Seattle, WA, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, ¹⁶Children's National Hospital, Washington, DC, ¹⁷George Washington University, Washington, DC, ¹⁸Columbia University, New York, NY, ¹⁹Mount Sinai School of Medicine, New York, NY, ²⁰Atlantic Health System, Morristown, NJ, ²¹University of Michigan, Ann Arbor, MI, ²²University of Kentucky, Lexington, KY, ²³University of Louisville, Louisville, KY, ²⁴Perinatal Associates of New Mexico, Albuquerque, NM, ²⁵Phoenix Children's Hospital, Phoenix, AZ, ²⁶Dignity Health, Phoenix, AZ, ²⁷University of Vermont Children's Hospital, Burlington, VT, ²⁸Yale University, New Haven, CT, ²⁹UH Rainbow Babies, Cleveland, OH, ³⁰Baylor College of Medicine, Houston, TX, ³¹Vanderbilt University, Nashville, TN, ³²Stanford University, Stanford, CA, ³³NYU Grossman School of Medicine, Brooklyn, NY, ³⁴University of Arizona College of Medicine, Tucson, AZ, ³⁵New York University Grossman School of Medicine, New York, NY
Background/Purpose: Maternal anti-SSA/Ro52/60kD autoantibodies are necessary for the development of fetal atrioventricular block (AVB) but titers alone are not sufficient to predict the likelihood of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].